Form 8-K - Current report:
SEC Accession No. 0001628280-24-021115
Filing Date
2024-05-07
Accepted
2024-05-07 16:22:22
Documents
30
Period of Report
2024-05-07
Items
Item 2.02: Results of Operations and Financial Condition
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K abcl-20240507.htm   iXBRL 8-K 28165
2 EX-99.1 q12024earningspressrelease.htm EX-99.1 153315
3 EX-99.2 abcelleraq12024businessu.htm EX-99.2 11803
7 abcelleraq12024businessu001.jpg GRAPHIC 42565
8 abcelleraq12024businessu002.jpg GRAPHIC 143507
9 abcelleraq12024businessu003.jpg GRAPHIC 60263
10 abcelleraq12024businessu004.jpg GRAPHIC 107982
11 abcelleraq12024businessu005.jpg GRAPHIC 110377
12 abcelleraq12024businessu006.jpg GRAPHIC 122417
13 abcelleraq12024businessu007.jpg GRAPHIC 69881
14 abcelleraq12024businessu008.jpg GRAPHIC 56746
15 abcelleraq12024businessu009.jpg GRAPHIC 83191
16 abcelleraq12024businessu010.jpg GRAPHIC 68172
17 abcelleraq12024businessu011.jpg GRAPHIC 71712
18 abcelleraq12024businessu012.jpg GRAPHIC 49965
19 abcelleraq12024businessu013.jpg GRAPHIC 64981
20 abcelleraq12024businessu014.jpg GRAPHIC 59290
21 capturea.jpg GRAPHIC 48406
  Complete submission text file 0001628280-24-021115.txt   1924010

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT abcl-20240507.xsd EX-101.SCH 1907
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT abcl-20240507_lab.xml EX-101.LAB 20678
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT abcl-20240507_pre.xml EX-101.PRE 11962
34 EXTRACTED XBRL INSTANCE DOCUMENT abcl-20240507_htm.xml XML 2593
Mailing Address 2215 YUKON STREET VANCOUVER A1 V5Y 0A1
Business Address 2215 YUKON STREET VANCOUVER A1 V5Y 0A1 (604) 559-9005
AbCellera Biologics Inc. (Filer) CIK: 0001703057 (see all company filings)

EIN.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39781 | Film No.: 24922329
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)